SITC Resource Library

Presentation slides from the 2025 Advances in Cancer Immunotherapy (ACI) Series: ACI Session at ACR Convergence 2025 were presented on October 27, 2025. 

Program Organizers

• Sophia Weinmann, MD, FACR – Duke University
• Jeffrey Sparks, MD, MSc – Brigham and Women's Hospital

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

• Delineate the current uses of cancer immunotherapy for different tumor types.
• Examine the risk of autoimmune disease flare or de novo irAE after ICI for patients with rheumatic disease.
• Recognize the risks and benefits of systemic steroids and certain steroid-sparing medications for patient with ICI-inflammatory arthritis.
• Create a management plan for a patient with a severe/refractory irAE (like ICI-sicca) or rare irAE.

You can view the program agenda here.

Please note on-demand recordings are not available for continuing education credits.